Show simple item record

dc.contributor.authorUslu, R.
dc.contributor.authorSzczesna, A.
dc.contributor.authorPolychronis, A.
dc.contributor.authorKrzakowski, M.
dc.contributor.authorLee, J.
dc.contributor.authorCalabro, L.
dc.contributor.authorFrontera, O.
dc.contributor.authorEllers-Lenz, B.
dc.contributor.authorBajars, M.
dc.contributor.authorRuisi, M.
dc.contributor.authorParki, K.
dc.contributor.authorOzguroglu, M.
dc.contributor.authorBarlesi, F.
dc.contributor.authorVansteenkiste, J.
dc.contributor.authorSpigel, D.
dc.contributor.authorIshii, H.
dc.contributor.authorGarassino, M.
dc.contributor.authorDe Marinis, F.
dc.date.accessioned2021-03-05T12:16:07Z
dc.date.available2021-03-05T12:16:07Z
dc.date.issued2018
dc.identifier.citationBarlesi F., Vansteenkiste J., Spigel D., Ishii H., Garassino M., De Marinis F., Ozguroglu M., Szczesna A., Polychronis A., Uslu R., et al., "Avelumab vs Docetaxel for Previously Treated Advanced NSCLC: Primary Analysis of the Phase 3 JAVELIN Lung 200 Trial", JOURNAL OF THORACIC ONCOLOGY, cilt.13, 2018
dc.identifier.issn1556-0864
dc.identifier.othervv_1032021
dc.identifier.otherav_ac55b84e-3fcf-4a86-b4f7-de4e36f6251f
dc.identifier.urihttp://hdl.handle.net/20.500.12627/115008
dc.identifier.urihttps://doi.org/10.1016/j.jtho.2018.08.260
dc.language.isoeng
dc.subjectSağlık Bilimleri
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectSOLUNUM SİSTEMİ
dc.subjectTıp
dc.subjectDahili Tıp Bilimleri
dc.subjectGöğüs Hastalıkları ve Allerji
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.titleAvelumab vs Docetaxel for Previously Treated Advanced NSCLC: Primary Analysis of the Phase 3 JAVELIN Lung 200 Trial
dc.typeMakale
dc.relation.journalJOURNAL OF THORACIC ONCOLOGY
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume13
dc.identifier.issue10
dc.contributor.firstauthorID257720


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record